The deal size was increased to $175M from $150M and priced below last closing price of $14.60. JPMorgan, Leerink and Cantor Fitzgerald are acting as joint book running managers for the offering.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Fulcrum Therapeutics price target raised to $7 from $6 at BofA
- Cautious Outlook for Fulcrum Therapeutics Amidst PIONEER Study Challenges and Market Uncertainties
- Fulcrum Therapeutics announces $150M offering of common stock
- Fulcrum Therapeutics price target raised to $25 from $20 at Stifel
- Fulcrum Therapeutics price target raised to $24 from $15 at Cantor Fitzgerald